Clinical trial to assess tolerability and subrogate efficacy effects of an abbreviated schedule with house dust mites mixture subcutaneous immunotherapyI. Antépara1, A. Roger2, N. Bernedo3, R. Lleonart4, F. Rodríguez5, B. Madariaga6,
J. A. Asturias6, L. Begoña6, A. Martínez6, A. Landeta6, M. C. Gómez-Fernández firstname.lastname@example.org
Show more: Authors information and Publication history
Department of Allergology, Hospital Universitario de Basurto, Bilbao, Spain2
Section of Allergology, Hospital Universitario Germans Trias Pujol, Badalona, Spain3
Department of Allergology, Hospital Universitario Araba, Vitoria, Spain4
Department of Allergology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain5
Department of Allergology, Hospital Universitario Marqués de Valdecilla, Santander, Spain6
Department of R&D, ROXALL Medicina España S.A., Zamudio, Spain
Published online: 22 February 2021
Accepted: 24 March 2020
Received: 20 January 2020
To evaluate the tolerability and efficacy of Dermatophagoides pteronyssinus/Dermatophagoidesfarinae mixture
subcutaneous immunotherapy (SCIT). Methods.
Patientsreceived an abbreviated build-up schedule. The aims were: number, percentage, and severityof adverse reactions. Secondary outcomes included: changes in immunoglobulin titers and changes in dose-response skin prick tests. Results.
Out of 289 administrations, 17% elicitedany clinically relevant adverse reaction. Most of them were local reactions (LR) (9.4%) and the rest (7.6%) were systemic. Significant increases in sIgG and sIgG4 were detectedin serum samples. Cutaneous reactivity decreased significantly. Conclusions.
SCIT withhouse dust mites mixture of ROXALL Medicina España S.A. seems to have an acceptabletolerability profile, induces blocking IgG and decreases skin reactivity.Key words
House dust mites; DPT/DF mixture; subcutaneous immunotherapy; rhinoconjunctivitis; abbreviated schedule.
Cite article as:
Antépara I, Roger A, Bernedo N, Lleonart R, Rodríguez F, Madariaga B, Asturias JA, Begoña L, Martínez A, Landeta A, Gómez-Fernández MC,Clinical trial to assess tolerability and subrogate efficacy effects of an abbreviated schedule with house dust mites mixture subcutaneous immunotherapy, Eur Ann Allergy Clin Immunol 2021;53(2):67-74. doi:10.23822/EurAnnACI.1764-1489.140.